Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Badra Enta-Soltane"'
Autor:
Karima Taibi, Ibtissem Kihel, Amine Abed, djaouad Guella, Badra Enta-Soltane, Yasmine Boukhatmi, Mohamed Amine Bekadja, Mourad Nachi
Publikováno v:
Journal de la Faculté de Médecine d’Oran; Vol. 4 No. 1 (2020); 525-530
Objectif - Dans le contexte de la leucémie myéloïde chronique (LMC), la recherche du transcrit de fusion BCR-ABL1 est devenue indispensable pour confirmer le diagnostic moléculaire. Dans cette étude, nous décrivons les différents types de tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c279cdf24dd58c6ea3d9e667937d5f82
https://www.ajol.info/index.php/jfmo/article/view/226770
https://www.ajol.info/index.php/jfmo/article/view/226770
Autor:
Badra Enta-Soltane, Mourad Nachi, Amine Abed, Ibtissem Kihel, Djaoued Guella, Mohamed Amine Bekadja, Mohamed Brahimi, Nabil Yafour
Publikováno v:
Hematology/oncology and stem cell therapy. 15(2)
Aim In chronic myeloid leukemia (CML), the impact of MBCR-ABL1 major transcript type on disease phenotype and response to treatment still controversial to date. This work aims to study the influence of Mb3a2 and Mb2a2 transcripts on clinico-biologica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee36a5fc106df90a2274942daedf35e
https://pubmed.ncbi.nlm.nih.gov/32971032
https://pubmed.ncbi.nlm.nih.gov/32971032
Autor:
Belmir I, Abed A, Boukhatmi Y, Guella D, Dali-Ali A, Kihel I, Badra Enta-Soltane, Mohamed Amine Bekadja, Mourad Nachi, Abou O, Houari T
Publikováno v:
Biochemistry & Pharmacology: Open Access.
Objective: The prognosis for chronic myeloid leukemia (CML) has been significantly improved in the era of tyrosine kinase inhibitors (TKIs) whose leader is Imatinib mesylate (IM). Obtaining a major molecular response (MMR) is a major objective to ach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02e35cb2e6a0ca0d3a885b9520a539e8
https://doi.org/10.35248/2167-0501.19.8.263
https://doi.org/10.35248/2167-0501.19.8.263
Autor:
Mohamed, Brahimi, Soufi, Osmani, Abdessamad, Arabi, Badra, Enta-Soltane, Zohra, Taghezout, Belkheir Smain, Elkahili, Mohamed Amine, Bekadja
Publikováno v:
Turkish Journal of Hematology, Vol 26, Iss 01, Pp 21-24 (2009)
The estimation of platelet count from blood smears is a daily routine laboratory test, which should be systematic each time the automated count is erroneous. In our laboratory, we estimate the platelet count indirectly by using the automated red bloo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b56b68561dad515bf985acbabf870158
http://www.journalagent.com/z4/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-30301
http://www.journalagent.com/z4/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-30301
Autor:
Rose-Marie Hamladji, M Belhani, Fz Brahimi, Farida Harieche, K Taibi, H Ghedira, A Maghraoui, A Trabzi, MT Abad, A Bouchakour, Y Meddour, N Boudjerra, Y Ben Youcef, Brahim Benzineb, S Gherras, M Saidi, Fz Touil, R. Ben Lakhal, M Attari, Fz Ardjoun, Z Zouaoui, Badra Enta-Soltane, T Ben Othman, Mohamed Amine Bekadja, Z Ouchenane, D Saber Cherif, A Graine, L Touati, HZ Manai, B Bendjabellah, Malek Benakli, C Kerrar, H Ait Ali, N Lakhdari, H Bellaaj, F Tibermacine, Mohamed Brahimi, N Mehalhal, Hadj Touhami, Ines Allam, S Hamdi, S Chaib, Samia Menif, A Bachiri, O Djidjik, S Taoussi, N Abdennebi, S Bougherira, B Meddeb, R Ahmed Nacer, N Sidi Mansour, Naima Mesli, K Djouadi, D Lamara, F Grifi, S Hadjeb, MA Laatiri, S Baghdad, F Kacha
Publikováno v:
Blood. 128:5440-5440
Introduction: Chronic myeloid leukemia (CML) accounts for 7%-15% of all leukemias affecting adults. The incidence in Algeria is 0.4/100,000 inhabitants in 2009. The aim of this study is to establish an Algerian-Tunisian epidemiological approach of CM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c844803a99f9b8098c97e96fa3064d47
https://doi.org/10.1182/blood.v128.22.5440.5440
https://doi.org/10.1182/blood.v128.22.5440.5440
Autor:
Y Meddour, Malek Benakli, M Zenori, M Belhani, L Allam, N Abdennebi, K Djouadi, Z Brahimi, Z Ouchenane, Rose-Marie Hamladji, A Bouchakour, Brahim Benzineb, C Rahali, D Lamara, S Gherras, Fz Ardjoun, N Sidi Mansour, S Hamdi, N Boudjerra, Karima Taibi, Naima Mesli, Hadj Touhami, Mourad Nachi, A Bachiri, S Chaib, S Hadjeb, S Baghdad, N Mehalhal, Badra Enta-Soltane, S Bougherira, F Grifi, Z Zouaoui, Mohamed Amine Bekadja, R Ahmed Nacer, N Lakhdari, D Saber Cherif, C Kerrar, O Djidjik, B Bendjabellah, Mohamed Brahimi, Fz Touil, N Mansour, Farida Harieche, MT Abad, L Touati, H Ait Ali, A Graine, F Maghraoui, S Taoussi, M Benlazhar
Publikováno v:
Blood. 128:5454-5454
Introduction: The advent of anti-tyrosine kinase has revolutionized the treatment of chronic myeloid leukemia. Indeed, from 2000, the IMATINIB has become internationally the gold standard of treatment for CML chronic phase, while the allogeneic bone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e23be95a17fe404e99d5ecceaeea7807
https://doi.org/10.1182/blood.v128.22.5454.5454
https://doi.org/10.1182/blood.v128.22.5454.5454
Autor:
Djamila Mansouri, Soufi Osmani, Badra Enta-Soltane, José Audouin, Mohamed Amine Bekadja, Mohamed Brahimi, Hanane Benredouane, Abdessamed Arabi, Nabil Yafour, Hamdane Mehadji
Publikováno v:
Hematology/Oncology and Stem Cell Therapy. 4(1):49-50
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77e62949f78414fc3de0a0d4ab7a4762